Australia's most trusted
source of pharma news
Thursday, 23 July 2026
Posted 23 July 2026 AM
The PBAC has dropped a hefty November meeting agenda, with a total of 63 submissions on the table, including a handful of innovative medicines yet to be approved by the TGA.
Overall, the reimbursement committee will consider 29 new PBS listing submissions, 29 change to existing listing submissions, three sub-committee DUSC analysis, plus two NIP listings covering MSD’s RSV antiviral monoclonal antibody Enflonsia and Moderna’s Covid jab mNEXSPIKE.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.